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DOI 10.1016/j.ccr.2011.01.039SUMMARYMutations in the PTEN, TP53, and RB1 pathways are obligate events in the pathogenesis of human glioblas-
tomas. We induced various combinations of deletions in these tumor suppressors in astrocytes and neural
precursors in mature mice, resulting in astrocytomas ranging from grade III to grade IV (glioblastoma). There
was selection for mutation of multiple genes within a pathway, shown by somatic amplifications of genes in
the PI3K or Rb pathway in tumors in which Pten orRb deletion was an initiating event. Despite multiple muta-
tions within PI3K and Rb pathways, elevated Mapk activation was not consistent. Gene expression profiling
revealed striking similarities to subclasses of human diffuse astrocytoma. Astrocytomas were found within
and outside of proliferative niches in the adult brain.INTRODUCTION
High-grade gliomas (HGGs), which are WHO grade III and IV
tumors, have a uniformly poor outcomewith themost aggressive
form, glioblastoma, a grade IV diffuse astrocytic tumor, bearing
a long-term survival of less than 10% (Louis et al., 2007). Animal
models that more accurately reflect HGG biology are needed to
advance our understanding of this disease as well as to allow for
more accurate preclinical testing of new treatment options.
The molecular pathogenesis of glioblastoma has been studied
in detail, including high-resolutionmicroarray analyses to identify
copy number (CN) imbalances and gene expression signatures
as well as in-depth sequence analyses to identify recurrent
targets of mutation. These studies concluded that glioblastoma
formation requires dysregulation in three core pathways: theSignificance
Induced gene deletion in astrocytes and progenitors in mature
cytomas (HGAs) most commonly arise, showed selective co
required for HGA formation induced by deletion ofPten,Rb1, or
mutations varied depending on the specific genes deleted. H
mutations relevant to human disease, and recapitulated all thre
gliomas by association with prognosis. Induction of Cre activity
ulations of neural progenitors in adult brain, suggesting that a
with lower efficiency.receptor tyrosine kinase (RTK)/phosphatidylinositol 30-kinase
(PI3K)/AKT axis, p53 signaling, and RB-mediated control of cell
cycle progression (Cancer Genome Atlas Research Network,
2008; Parsons et al., 2008). Genetic aberrations affecting inter-
mediates of all three pathways are identified in virtually all
glioblastomas. For the RTK/PI3K pathway, biallelic inactivation
of PTEN through mutation coupled with LOH of chromosome
(Chr) 10q is a common mechanism in glioblastoma to abrogate
the major negative regulator restraining PI3K activation. The
most common RTK target of mutation is amplification of EGFR,
often coupled with intragenic deletion resulting in a constitutively
activated form. p53 signaling is dysregulated frequently by bi-
allelic inactivation of TP53, or in some cases byHDM2 amplifica-
tion. Homozygous deletions of CDKN2A simultaneously remove
p14ARF, a negative regulator of p53 signaling, as well as INK4A,brain, the developmental setting in which high-grade astro-
operativity among tumor suppressors. Tp53 deletion was
combinedPten;Rb1 deletion. Tumor latency and secondary
GAs contained a spectrum of focal and large-scale somatic
e gene expression subgroups previously identified in human
was widespread in astrocytes and restricted to limited pop-
strocytomas can develop outside of proliferative niches, but
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Tumor Suppressors in High-Grade Astrocytomaa key regulator of the RB-mediated G1 checkpoint, thus impact-
ing both p53 and RB pathways. Mutations in RB1 are also found
in glioblastoma (Cancer Genome Atlas Research Network, 2008;
Parsons et al., 2008).
The effects of Pten, Rb1, or Tp53 deletion in the mouse brain
have been described through the use of mouse lines expressing
Cre specifically in the brain. For the most part the phenotype
obtained is cell-type and developmental-stage specific. For
example, deletion of Pten in neural stem and progenitor cells
resulted in expansion of the stemcell niche, a proliferative advan-
tage in the progenitor cell population as well asmigration defects
causing a disruption in the laminar structure of the cortex (Grego-
rian et al., 2009; Groszer et al., 2001). In contrast, ablation ofPten
in postmitotic cerebellar neurons resulted in cellular hypertrophy
(Backman et al., 2001; Kwon et al., 2001; Marino et al., 2002).
Pten null astrocytes showed evidence of hypertrophy and prolif-
eration (Fraser et al., 2004; Wei et al., 2006) and abnormal migra-
tion (Yue et al., 2005). In the case of Rb1, conditional ablation at
E9 in the telencephalon or the whole brain resulted in cell cycle
defects characterized primarily by increased proliferation (Fergu-
son et al., 2002;MacPherson et al., 2003). Conditional deletion of
Tp53 combined with haploinsufficiency of Nf1 and Pten, or dele-
tion of Nf1, generated high-grade astrocytomas (HGAs) (Alcan-
tara Llaguno et al., 2009; Kwon et al., 2008; Zheng et al., 2008).
In contrast an intragenic deletion of Tp53 encoding a mutant
protein, induced in embryonic brain, was sufficient to cause
malignant astrocytomas in mid-adulthood (Wang et al., 2009).
Although the exact histogenesis of gliomas is still a matter of
some controversy, there is agreement that neural progenitor
cells or mature astrocytes are likely candidates (Louis et al.,
2007).We recently reported the characterization ofGFAP-CreER
mice with inducible targeting of approximately 50% of mature
astrocytes, and less than 1% of neural precursor cells located
in the subventricular zone (SVZ) and subgranular zone (SGZ) of
the dentate gyrus (Chow et al., 2008). Here, we used this
GFAP-CreERmouse line to study the tumor suppressor function
of Pten, Tp53, and Rb1 in the development of HGAs in mature
brain because this is the context in which themajority of glioblas-
tomas arise.
RESULTS
Minimal Effects of Pten Deletion in Mature Astrocytes
We generatedGFAP-CreERTMA (hereafter referred to asCreER);
PtenloxP/loxP mice to investigate the effect of Pten loss in mature
astrocytes. Cre activity was transiently induced in developmen-
tally maturemice by tamoxifen administration after postnatal day
(P) 21 (range P20–P45). Recombination and inactivation of Pten
were confirmed by real-time PCR (see Figure S1A available on-
line). Conditional deletion of Pten in mature brain did not reduce
survival (Figure S1B) or disrupt brain architecture (Figures 1A–
1C). There was a modest increase in Gfap expression in the
brains of Pten conditional knockout (cKO) mice (Figures 1A–
1F; Figure S1C, lanes 7–9), a feature also observed in primary
cultures of Pten null astrocytes (data not shown). However, we
did not detect astrocyte hypertrophy or hyperproliferation (data
not shown).
Pten is the central negative regulator of the PI3K/Akt pathway
(Chow and Baker, 2006). In rare Pten null granule neurons of the306 Cancer Cell 19, 305–316, March 15, 2011 ª2011 Elsevier Inc.dentate gyrus that were targeted by this CreER strain, we de-
tected the expected increase in phosphorylation of Akt (pAkt)
at S473 or phosphorylation of S6 (pS6) at S235 and S236, indi-
cating hyperactivity of the PI3K/Akt pathway (Figures S1D–S1I,
arrows). However, western blot analyses of cortical lysates and
immunohistochemistry (IHC) did not detect any perturbations
in pathway signaling induced by Pten deletion in astrocytes
(Figures 1G–1I; Figure S1C). Therefore, inactivation of Pten in
adult astrocytes did not induce detectable activation of PI3K
signaling and, accordingly, did not lead to an overt phenotype
or tumor predisposition.
Combined Inactivation of Pten and Tp53 Induced HGA
Highly penetrant HGAs were induced in CreER; PtenloxP/loxP;
Tp53loxP/loxP compound mice, hereafter termed Pten; p53 cKO
mice. Cre activity was induced in adult mice as described above.
Pten; p53 cKO mice had a significantly reduced survival
compared to Pten cKOmice, or to PtenloxP/+; p53 cKOmice (Fig-
ure 2A). Fifty-five of 63 (87%) Pten; p53 cKO brains harbored
tumors within the spectrum of HGA, showing a range of histo-
pathological features. Approximately 25% of tumors were clas-
sified as glioblastomas, on the basis that they featured scattered
cells with an astrocytic phenotype, mitotic activity, cytological
pleomorphism, including in some cases a substantial number
of multinucleated giant cells (Figure 2B), necrosis (Figure 2C),
and/or microvascular proliferation (Figure 2D). Approximately
25% of tumors were anaplastic astrocytomas with myxoid
degeneration, a feature more commonly observed in pediatric
gliomas than adult (Figure 2E). Half of the tumors were diffuse
anaplastic astrocytomas, demonstrating infiltrating tumor cells
(Figure 2F) and a focal astrocytic phenotype. In some cases
there was extensive parenchymal infiltration combined focally
with the architectural and cytological features of gliomatosis
(Figure 2G). PCR analysis confirmed inactivation of the Tp53
locus (Figure S2), and Pten IHC showed that tumor cells were
Pten null (Figures 2H–2J), highlighting invasion by tumor cells
of perivascular spaces (Figure 2I), leptomeninges (Figure 2J),
and parenchyma.
Tumors consistently showed elevated pAkt (Figure 3A), and
were highly proliferative, as shown by Ki67 IHC (Figure 3B).
Active Caspase-3, a marker of apoptosis, was also detectable
in most tumors (Figure 3C). Immunophenotyping of the tumors
revealed Gfap and S100b immunoreactive tumor cells in varying
proportions (Figures 3D; data not shown). Neurofilament (light-
chain) IHC was negative in tumor cells (Figure 3E). Nestin,
a marker of neural progenitor cells (Brustle and McKay, 1995),
was also expressed in tumors (Figure 3F).
Tumors Developed within and outside
of Proliferative Niches
The location of tumors within the CNS included all regions of the
forebrain, midbrain, hindbrain, and spinal cord, and did not
correlate to different histopathological features. Many tumors
were contiguous with regions rich in neural progenitor cells,
such as the SVZ, the rostral migratory stream (RMS), and SGZ
of the dentate gyrus (Figures S3A and S3B). When tumors
were not macroscopically evident, serial sectioning and H&E
frequently revealed small groups of tumor cells invading through
white matter tracts adjacent to zones rich in neural progenitors,
Figure 1. Pten Deletion in Adult Astrocytes
Does Not Disrupt Brain Architecture or
Activate Akt
(A–C) Sagittal sections were immunostained for
Gfap (brown) and counterstained with hematox-
ylin. Magnified views of boxed regions for Gfap
IHC (D–F) and pAkt S473 IHC (G–I, brown) are
shown.
(A, D, and G) PtenloxP/loxP mouse injected with
tamoxifen. (B, E, and H) CreER; PtenloxP/loxP
mouse injected with vehicle.
(C, F and I) CreER; PtenloxP/loxP mouse injected
with tamoxifen.
Scale bar in (A) is 1 mm and applies to (A)–(C).
Scale bar in (D) is 50 mm and applies to (D)–(I).
See also Figure S1.
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Tumor Suppressors in High-Grade Astrocytomasuch as the corpus callosum and internal capsule (Figures S3C–
S3H, arrows). These cells were highly proliferative (Figures S3F–
S3H and insets) and Pten null (Figure S3K, arrow). They may
represent early stages of tumor growth or indicate cells in transit
toward distant sites. Significantly, 22% (14/63) of tumors devel-
oped in sites independent of proliferative niches, including the
cerebellum, spinal cord, or the ventral brain stem (Figures 3G–
3I), in the absence of any other microscopically detectable tumor
or abnormally proliferating cells in the brain including the progen-
itor niches, eliminating the possibility that they arose by spread
from a distant established tumor mass. Although it is possible
that tumor-initiating cells originating fromprogenitor-rich regions
populated these tumors, we also identified early lesions and
hyperproliferative cells in the cerebellum of brains where no
aberrant proliferation in progenitor niches was apparent (Figures
S3I and S3J, and inset).
CommonRTKAmplification andOverexpression inPten;
p53 cKO Mouse HGA
Array comparative genomic hybridization (aCGH) analysis re-
vealed that most tumors carried multiple focal amplifications
(CN >3) and deletions (CN <1.5), large-scale CN gains and los-
ses, and more complex patterns of chromosomal copy number
alterations (CNAs). The most frequent focal amplification,
present in 24% (12/50) of tumors (ten of these with CN >3),
was localized to Chr6A2 and included Met (Figure 4A), which
encodes an RTK amplified in human glioblastomas, as well as
other genes, some with association to HGG (Table S1). Addi-
tional focal amplifications involved Egfr and Pdgfra, encoding
twoRTKs that have been strongly implicated in the pathogenesis
of HGG (Furnari et al., 2007). The region including Egfr was
focally amplified in four tumors (Figure S4A), whereas the
majority of Chr11 containing Egfr was amplified to a high degree
in an additional tumor. Reverse transcription (RT)-PCR of Egfr
transcripts from tumors with or without amplification did not
detect truncations analogous to the EGFR vIII mutated variant
found in some human glioblastomas (data not shown). The
Pdgfra gene was contained within regions of high-level focalCancer Cell 19, 305–316amplification in two tumors, and regions
of focal gain (CN ranging from 2.3 to 3)
in an additional five tumors (Figure S4B).
All except one of the Pdgfra ampliconsincluded the gene encoding the RTK Kit. Large-scale gains of
Chr5, including Pdgfra, were found in an additional nine tumors.
Most of the amplifications and gains of the three RTK genes
described were mutually exclusive, although three tumors had
concurrent focal amplifications of Met and another RTK. Thus,
40% (20/50) of Pten; p53 cKO tumors contained somatic focal
CNAs in these three RTK genes.
Gene amplification was confirmed by fluorescence in situ
hybridization (FISH) (Figures 4A; Figures S4A and S4B). Real-
time RT-PCR showed that focal amplification was consistently
associated with high expression levels of the targeted RTK (Fig-
ure S4C). Several HGAs overexpressed RTKs, most frequently
Pdgfra, in the absence of a detectable gene amplification event,
as has been observed in human astrocytomas (Furnari et al.,
2007). Western blot analysis showed that Met (lanes 7–9) and
Egfr (lanes 3 and 5) overexpression in HGG was correlated with
gene amplification, whereas Pdgfr-a was overexpressed in the
majority of HGA samples and did not correlate with CN (Fig-
ure 4B). As expected for Pten-deficient tumors, levels of pAkt
were elevated compared to normal cortex (Figures 3A and 4B).
Interestingly, levels of pMapk T202/Y204 were not consistently
altered among tumor samples, suggesting that steady-state
signaling through the Ras/Mapk pathway was not necessarily
elevated in HGA. There was no consistent correlation between
RTK overexpression and tumor histology, or with levels of pMapk
T202/Y204. Levels of pS6 S235/236 were more variable and
tended to correlate with total S6 protein levels (Figure 4B).
Rb1 Deletion Further Contributed to Tumor Formation
in cKO Mice
To model the concurrent dysregulation of the RTK/PI3K/AKT,
p53, and RB pathways found in the majority of HGGs (Cerami
et al., 2010; Cancer Genome Atlas Research Network, 2008;
Parsons et al., 2008), we generated CreER; PtenloxP/loxP;
Tp53loxP/loxP; Rb1loxP/loxP compound mice (hereafter termed
triple cKO mice) and induced Cre activity as described above.
Deletion of Rb1 in addition to Pten and Tp53 significantly
reduced the latency of tumor development and time to morbidity, March 15, 2011 ª2011 Elsevier Inc. 307
Figure 2. HGAs Arising from Pten; p53 cKO
Mice
(A) Kaplan-Meier survival analysis on tamoxifen-
induced cohorts consisting of Pten cKO (n = 34;
blue), PtenloxP/+; p53 cKO (n = 6; green), and
Pten; p53 cKO mice (n = 148; red).
(B–G) H&E of Pten; p53 cKO brains showing
recurrent histological features: glioblastoma with
multinucleated giant cell phenotype (B, arrow),
necrotic foci (C, nec) and sometimes microvas-
cular proliferation (D, arrow), and anaplastic
astrocytoma with myxoid degeneration (E) and
diffusely infiltrating tumor cells (F) sometimes
consistent with gliomatosis (G).
(H–J) IHC for Pten (brown) counterstained with
hematoxylin highlighting areas of perivascular
invasion (I) and leptomeningeal spread (J). Arrows
in (I) indicate a blood vessel, whereas the arrow in
(J) points to the pial membrane overlying tumor
cells. Scale bar in (B) is 20 mm and applies to
(B)–(F) and (H). Scale bar in (G) is 200 mm. Scale
bar in (J) is 50 mm and applies to (I) and (J).
See also Figure S2.
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brains, 85% (26/31) contained HGAs encompassing the same
histological variation observed inPten; p53 cKOmice (Figure 5B;
data not shown). Deletion of Pten in tumors was confirmed by
IHC (Figure 5C), and deletion of Tp53 and Rb1 was demon-
strated by PCR (Figures S5A and S5B). Triple cKO and Pten;
p53 cKO tumors showed similar high proliferation rates (Figures
5D; Figure S5C), invasive properties and immunophenotypes
(data not shown), and pathway activation, with consistently
elevated pAkt at S473 and T308 and variable pS6 S235/236
and p-Mapk (Figure 6).
aCGH showed a significant difference in the selective pressure
for amplifications with no focal amplifications of the RTKs Met
and Egfr in triple cKO tumors compared to 30% of Pten; p53
cKO tumors showing focal amplification of one or both of these
genes (p = 0.003). Large-scale gains of the Chrs containing these
genes were also not consistently associated with RTK overex-
pression in triple cKO tumors (Figure 6). However, the frequency
of Pdgfra amplification was very similar between Pten; p53 cKO
tumors and triple cKO tumors (14% in both; p = 1), and both sets
of tumors showed frequent overexpression of Pdgfra, even in the
absence of focal amplification (Figures 4 and 6). Thus, Rb1 inac-308 Cancer Cell 19, 305–316, March 15, 2011 ª2011 Elsevier Inc.tivation further cooperated with Pten and
Tp53 deletions to generate HGAs with
similar histopathological and biochem-
ical signatures, but different selective
pressure for RTK amplifications.
Similar CNAs in cKOMouseTumors
and Human HGA
In addition to genes encoding the RTKs
mentioned previously, other notable
genes contained within regions of CNA
included amplification of Cdk4, Cdk6,
Ccnd1, Ccnd2, and Ccnd3, which
directly regulate Rb activity at the G1/Scell cycle checkpoint, as well as loss ofDcc and Smad4. Expres-
sion changes in all of these genes have been implicated in glioma
biology (Buschges et al., 1999; Kjellman et al., 2000; Cancer
Genome Atlas Research Network, 2008; Reyes-Mugica et al.,
1997). Of 50 Pten; p53 cKO tumors, 12 (24%) had an amplifica-
tion or deletion in at least one gene that would be expected to
promote progression through the cell cycle (Table S2). Analysis
of Rb null tumors showed that three of 21 tumors (14%) also
had focal mutations in key cell cycle regulatory genes (p = 0.5),
although these did not involve the upstream regulators of Rb
(Table S2). We observed large deletions of Chr14 that included
the Rb1 locus in four of 50 Pten; p53 cKO tumors (8%); however,
similar deletions of Chr14 were also detected in six of 21 triple
cKO tumors (29%), suggesting that Rb1 was not the critical
gene targeted by these deletions. Finally, Mycn, which has
been proposed to promote cell cycle progression in the context
of tumorigenesis (Pession and Tonelli, 2005), was amplified or
gained in five (10%) Pten; p53 and four (19%) triple cKO tumors
(Figure S6A). Thus, the data support the notion that dysregula-
tion of cell cycle regulation through additional mutations
provides additional selective advantages above that provided
by Rb1 loss alone.
Figure 3. Immunophenotype of Pten; p53
cKO HGAs
(A–C) Sections from a brain containing anaplastic
astrocytoma were immunostained for pAkt S473
(A, brown), Ki67 (B, purple), and active Caspase-3
(C, purple), counterstained with hematoxylin (A) or
methyl green (B and C). The dashed line indicates
the approximate interface between normal cere-
bral cortex above and tumor below.
(D–F) IHC (brown) of anaplastic astrocytoma for
Gfap (D), the light chain of Neurofilament (E), and
Nestin (F), counterstained with hematoxylin. The
arrow in (E) indicates the soma of a neuron.
(G–I) H&E showing tumors in the cerebellum (Cbl),
spinal cord (SpC), and growing as an exophytic
mass from the pons. Scale bar in (D) is 50 mm
and applies to (A)–(F). Scale bars in (G) and (H)
are 200 mm. Scale bar in (I) is 1 mm.
See also Figure S3.
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two models (Figure 7). The region of Chr12 that is deleted in
54% of Pten; p53 and 52% of triple cKO tumors shares synteny
with human Chr14q, which is lost in 25% of glioblastomas.
Similarly, partial loss of Chr14, occurring in 20% of Pten; p53
and 43% of triple cKO tumors (p = 0.08), is syntenic to both
human Chr14q and 13q, which undergo LOH in 30% of glio-
blastomas. In fact, with the exception of Chr10q (which contains
the PTEN locus), Chr14q and 13q losses are among the most
frequent in glioblastoma (Cancer Genome Atlas Research
Network, 2008; Parsons et al., 2008). Other significant large
CNAs occurring in both models include loss of Chr9 and Chr18
and gain of Chr3, whereas partial deletion of Chr16 was more
common in Pten; p53 cKO tumors (p = 0.003). One of the more
frequent focal deletions noted in triple but not in Pten; p53
cKO tumors involves Lrp1b, which was lost in 43% (nine of 21)
of tumors (Figure S6B), including six intragenic deletions.
LRP1B deletions, including intragenic deletions, have been
reported in glioblastoma (Parsons et al., 2008; Paugh et al.,
2010; Yin et al., 2009; Zarghooni et al., 2010) as well as other
tumor types (Cengiz et al., 2007; Langbein et al., 2002; Na-
gayama et al., 2007; Nakagawa et al., 2006; Sonoda et al.,
2004). Taken together, the genomic landscapes of tumors
arising from these murine HGA models are similar to each other
and, more importantly, resemble human glioblastomas.
Gene Expression Signatures from Mouse HGAs
Significantly Resemble Human Disease
Gene expression profiles were analyzed for 24 Pten; p53 and 14
triple cKO HGAs. Unsupervised hierarchical clustering segre-
gated the tumors into three distinct subgroups (Figure 8A; hierar-
chical cluster [HC] 1–HC3). Tumors from each cKO background
were present in all three subgroups, further demonstrating that
similar HGAs arise despite differences in the number of initiatingCancer Cell 19, 305–316mutations. Grade III anaplastic astrocy-
tomas or pilomyxoid tumors did not
cluster with specific subgroups; how-
ever, glioblastomas were exclusively
found in HC2 and 3, not in HC1 (p =0.0001). Notably, 38% (11/29) of HC1 and HC2 tumors, and
none of the HC3 tumors, had focal amplifications in RTK genes
(p = 0.04; Figure 8A). Several studies have identified gene
expression subgroups in human HGG. Using gene set enrich-
ment analysis (GSEA), we demonstrated highly significant
similarity among the expression signatures of the mouse HC1,
HC2, and HC3 subgroups with the human HGG expression
subgroups that were identified by comparing prognosis, termed
Proneural, Proliferative, and Mesenchymal, respectively (Phillips
et al., 2006) (Figure 8B; Table S3). The Cancer Genome Atlas
Project (TCGA) identified four expression subgroups that corre-
late to some extent with specific combinations of mutations
(Verhaak et al., 2010), and there was also significant similarity
between signatures in mouse HC1, with the TCGA Proneural
and Neural subgroups, HC2 with the Proneural subgroup, and
HC3 with the Mesenchymal subgroup (Table S3). Single-sample
GSEAwas also used to demonstrate the correlation of each indi-
vidual mouse tumor gene expression profile with the gene sets
for each human subgroup (Figure 8C). Interestingly, 78% (seven
of nine) of the mouse HC3 tumors were exophytic tumors arising
from the basal hypothalamus or the ventral pons (Figures 3I and
8A). To determine if this location was strongly associated with
a specific expression signature in human tumors from similar
locations, we analyzed the gene expression signatures of six
human exophytic gliomas arising from the brain stem along
with published data from pediatric HGG (Paugh et al., 2010)
and adult glioblastoma (Lee et al., 2008). Single-sample GSEA
showed heterogeneity among the human exophytic brain stem
gliomas, with 33% (two of six) showing significant similarity to
the Mesenchymal subclass, whereas 67% (four of six) showed
the most significant similarity to the Proneural subclass (Fig-
ure S7). Similarly, we found gene expression signature heteroge-
neity among 31 grade IV human diffuse intrinsic pontine gliomas,
with a similar proportion showing significant similarity to the, March 15, 2011 ª2011 Elsevier Inc. 309
Figure 4. Focal Amplification, Signaling Pathway Activation, and
Overexpression of RTKs in Pten; p53 cKO HGA
(A) Recurrent focal amplification of Met in Pten; p53 cKO HGA. aCGH plot
of Chr6 location on the x axis and log2 ratio on the y axis is shown for a
representative tumor (left panel). Amplified region containingMet is indicated.
The middle panel is a heat map of log2 ratio showing focal CN gains in 13
tumors (horizontal bars) in the amplified region surrounding Met. The
boxed region contains Met. Color scale with corresponding log2 ratio value
is below. The right panel illustrates FISH on same tumor as left panel showing
amplification ofMet (green) compared to control Chr6 probe (red). Scale bar is
2 mm.
(B) Survey of pathway activation and RTK expression in Pten; p53 cKO HGAs.
Lysates from Pten; p53 cKO mice were prepared from cortex that was grossly
free of tumor (lanes 1 and 2) or from HGAs demonstrating a variety of histolog-
ical features (lanes 3–16) and analyzed by western blots with the indicated
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310 Cancer Cell 19, 305–316, March 15, 2011 ª2011 Elsevier Inc.Mesenchymal subgroup (unpublished data). Thus, the Mesen-
chymal signature found in the majority of mouse exophytic
tumors arising from the brain stem or basal hypothalamus was
also found in a subset of human gliomas arising from the brain
stem.
Tp53 Loss Was Required for Gliomagenesis
To examine the cooperativity between tumor suppressors in the
triple cKO mice, Pten; Rb1 cKO and p53; Rb1 cKO mice were
also evaluated. No brain tumors were detected in 38 Pten; Rb1
cKO brains that were serially sectioned in their entirety, although
eight had pituitary tumors, which have been noted in Rb1+/
mice. Of 19 Rb1; p53 cKO mice, 13 (68%) developed brain
tumors with prolonged latency compared to Pten; p53 cKO
mice (Figure S5D). Two of these mice had tumors of morphology
consistent with primitive neuroectodermal (PNET), although they
did not show robust synaptophysin staining. An additional three
mice had tumors within the olfactory bulb with strong resem-
blance to human olfactory neuroblastoma. Ten of 13 mice with
brain tumors had HGA with histopathological features compa-
rable to tumors from the other models (Figures S5E–S5G; data
not shown). All but one of the tumorsmaintained Pten expression
(Figures S5H–S5J). However, pAkt expression was strong
throughout seven of 13 tumors (54%) (Figures S5K and S5L),
and showed patchy or lower-level staining in an additional three
tumors, indicating that the PI3K/AKT pathway is engaged in the
majority of Rb1; p53 cKO tumors.
DISCUSSION
Tumor Suppressor Cooperativity in Astrocytoma
Induced gene deletion in the adult brain reveals selective coop-
erativity among key tumor suppressors in the developmental
context where the majority of HGAs arise. The high penetrance
of HGA in mice with induced combined mutation of Pten,
Tp53, andRb1 shows that the same core pathways drive glioma-
genesis in mouse and human. The mutation spectrum in human
glioblastomas has been extensively studied. More than 90% of
human glioblastomas are primary glioblastomas that arise de
novo without clinical or histological evidence of progression
from a preexisting lesion (Louis et al., 2007). In the absence of
clear progression, there is no unambiguous indication whether
specific frequent genetic mutations arise preferentially as early
or late events. This timing is implied by the analysis of tumor
progression for the less-common secondary glioblastomas
that arise as a consequence of malignant transformation from
low-grade diffuse astrocytomas. However, there are distinct
differences in the molecular pathogenesis of primary and
secondary glioblastomas. Most significantly, IDH1 mutations
occur in more than 70% of secondary glioblastomas and the
lower-grade lesions from which they arise but are rare in primary
glioblastomas (Yan et al., 2009). This suggests that primary glio-
blastomas lack a common initiating mutation found in secondaryantibodies. TheMet,Egfr, andPdgfra gene CNs below the corresponding blots
are calculated from log2 ratio values obtained from aCGH on the same tumor
sample.
See also Figure S4, and Tables S1 and S2.
Figure 5. HGAs Arising from Triple cKO
Mice
(A) Kaplan-Meier survival analysis was performed
on tamoxifen-induced cohorts consisting of Pten;
p53 (n = 148; red) and triple cKO mice (n = 35;
blue).
(B) H&E of a triple cKO brain containing a giant cell
glioblastoma.
(C) IHC for Pten (brown) on a section correspond-
ing to the same tumor counterstained with hema-
toxylin.
(D) IHC for Ki67 (purple) on an adjacent section
counterstained with methyl green. Scale bar in
(C) is 50 mm and applies to (B)–(D).
See also Figure S5.
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Thus, the role of common mutations in primary glioblastoma to
act as initiating or late events remains unclear.
Using mouse models, we induced mutations in specific key
tumor suppressors and evaluated which mutations cooperated
to cause glioma, and which additional mutations provided a
selective advantage. In our models none of these tumor sup-
pressor deletions alone induced astrocytomas with high
frequency, although Tp53 deletion induced late onset, low-
frequency astrocytomas similar to a previous study (Zheng
et al., 2008) (data not shown). The greatest cooperativity and
earliest tumor onset occurred with simultaneous mutation of all
three tumor suppressors, consistent with concurrent mutations
in these three pathways occurring in virtually all human glioblas-
tomas. Combinations of mutations that included Tp53 induced
astrocytomas efficiently. This supports a role for Tp53 inactiva-
tion in astrocytoma initiation and is consistent with the high
frequency of TP53 mutations and low frequency of RB1 and
PTEN mutations in grade II human astrocytomas (Louis et al.,
2007; Wen and Kesari, 2008). The significantly earlier onset of
tumors arising from Pten; p53 deletion compared to Rb1; p53
deletion demonstrated that Pten loss cooperated more effec-
tively thanRb1 deletion with p53mutation. Importantly, we failed
to detect any brain tumors arising from mice with targeted
codeletions in Rb1 and Pten. This does not necessarily indicate
that these two pathways fail to cooperate in gliomas but, rather,
indicates that the specific mutation of Pten and Rb1 does not
effectively cooperate in the absence of other mutations. In
another study, expression of a truncated SV40 T antigen that
inactivates all Rb family members induced mouse astrocytomas
and cooperated with Pten loss (Xiao et al., 2005). This suggests
that inactivation of all Rb family members may be required to
initiate gliomagenesis or that the truncated T antigen exerted
additional Rb-independent effects.Cancer Cell 19, 305–316PTEN functions primarily by regulating
RTK/PI3K/AKT signaling through its lipid
phosphatase activity. Loss of Pten in
several cell types within the brain during
development, including neurons, astro-
cytes, and neural progenitor cells, has
been shown to result in Akt activation
and proliferation, but not tumorigenesis
(Fraser et al., 2004; Gregorian et al.,2009; Groszer et al., 2001; Kwon et al., 2001). We found that
Pten loss in the mature astrocyte induced elevated Gfap expres-
sion but did not demonstrate features of severe astrocytic
gliosis, such as hypertrophy, hyperproliferation, and abnormal
multinucleated astrocytes. Thus, Pten loss may disrupt cellular
homeostasis enough to be detected as a cellular stress inducing
a low-level astrogliosis response, but it is insufficient to drive
proliferation, consistent with the inability to initiate gliomagene-
sis in the absence of other mutations. Importantly, Pten loss
did not substantially stimulate PI3K signaling, suggesting that
in this context, basal signaling through the RTK/PI3K axis is
not sufficient to elevate pathway activity, even in the absence
of negative regulation. This is consistent with the cell type-
specific feedback regulation that inhibits PI3K signaling in glia,
but not in neurons (Chalhoub et al., 2009). Therefore, the net
outcome of mutations that deregulate PI3K signaling depends
on the cellular and developmental context.
Site of Astrocytoma Development
To precisely define a cell of origin for a tumor in a model system,
it is necessary to use highly selective methods to induce gene
mutations only in specific populations of cells. Using this
approach, several recent reports identified neural progenitor
cells as the likely cell of origin for HGAs in mouse models and
showed that cells outside of the proliferative niche failed to
form HGAs with combinations of deletion in Pten, Tp53, Nf1,
and Rb1 (Alcantara Llaguno et al., 2009; Holland et al., 2000;
Jacques et al., 2010; Wang et al., 2009). In contrast, the goal
of this study was to induce widespread tumor suppressor dele-
tion in astrocytes and progenitor cells in the adult brain to test the
ability of these mutations to induce gliomas in diverse brain
regions. Using GFAP-CreER mice, we induced Cre activity in
a much larger population of cells outside of proliferative niches
than within the neurogenic zones of adult brain. We found, March 15, 2011 ª2011 Elsevier Inc. 311
Figure 6. Signaling Pathway Activation in Triple cKO Mice
Lysates from triple cKO mice were prepared from cortex that was grossly free
of tumor (lanes 1–5) or from HGAs demonstrating a variety of histological
features (lanes 6–19) and analyzed by western blots with the indicated anti-
bodies. The Met, Egfr, and Pdgfra gene CNs below the corresponding blots
are calculated from log2 ratio values obtained from aCGH on the same tumor
sample. One tumor sample (lane 13) did not have a corresponding aCGH
profile (ND).
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Tumor Suppressors in High-Grade AstrocytomaHGAs both within and outside of proliferative niches, and hetero-
geneity in tumor histopathology was independent of location.
Human glioblastomas also often occur in regions not associated
with neurogenesis. Our analysis may underestimate the
frequency of tumors arising outside of the neurogenic niche
because we evaluated tumors at the time of morbidity, where
large tumors that may have arisen in surrounding regions and
grown into the neurogenic niche were scored as associated
with proliferative zones. The higher frequency of tumors arising
in association with proliferative niches is consistent with progen-
itor/stem cells having a greater propensity formalignant transfor-
mation. Indeed, despite much lower Cre activity in neurogenic
niches, tumors arose predominantly in areas contiguous with
or adjacent to neural stem cell niches in the brain, and we also312 Cancer Cell 19, 305–316, March 15, 2011 ª2011 Elsevier Inc.detected early invasion of proliferative tumor cells through white
matter tracts in these regions (Figures S3C–S3H). Nevertheless,
macroscopic HGAs and microscopic proliferative lesions were
also found in areas isolated from canonical neural progenitors
in mice without detectable hyperplasia or abnormalities in prolif-
erative zones (Figures 3G–3I; Figures S3I, and S3J). Although the
precise cell of origin remains to be determined, these tumors
may arise from mature astrocytes (Dufour et al., 2009), locally
resident progenitor cells (Laywell et al., 2000; Lee et al., 2005),
or progenitor cells that escaped from proliferative niches to
populate distant sites.
Recently, Jacques et al. (2010) reported that tumors arising
from p53; Rb1 or Pten; p53; Rb1 codeletions induced in SVZ
cells, presumably neural stem cells and/or progenitor cells,
were almost exclusively of the PNET phenotype, whereas
Pten; p53 codeletion resulted in gliomas. In contrast, all of these
combinations of tumor suppressor inactivation induced in adult
mice by GFAP-creER gave rise to HGAs, consistent with
concurrent mutation of these pathways in human HGAs. None
of the tumors arising in triple cKO mice was a typical PNET
on the basis of histopathological features, lack of synaptophysin
expression, and the consistent expression of Gfap (data not
shown). The discrepancies between tumor types obtained could
be explained by differences in the specific cells targeted by
adeno-Cre virus injections into the ventricle compared to
GFAP-CreER, the age of the mice at the time of tumor
suppressor inactivation, inflammation and wound healing
secondary to the intracranial injection procedure, differences
in genetic background, or differences in the Pten floxed strain
used in the two studies.
Initiating Mutations Drive Selective Pressures for
Additional Disruption within the Same Core Pathways
Genome-wide analysis of CNAs in mouse HGAs revealed strong
selective pressure in Pten; p53 cKO tumors for focal amplifica-
tions in the RTKs Met, Egfr, and Pdgfra, genes that are also
well-known amplification targets in human glioblastoma (Furnari
et al., 2007). These somatic amplifications in upstream compo-
nents of PI3K signaling strongly suggest that Pten deletion alone
was insufficient to activate the pathway to the levels required to
drive gliomagenesis in this model and/or that pathways down-
streamof RTKs other than PI3K/Akt are required for HGA growth.
Although RTKs are known to signal through both the Mapk and
PI3K pathways, in the mouse HGAs, RTK amplifications were
associated with consistently high PI3K signaling, but not consis-
tently elevated Mapk signaling. This demonstrates that the
downstream consequences of RTK activation vary in gliomas.
Somatic mutations also demonstrated that amplifications of
different RTKs were not equivalent. Pdgfra amplification and
overexpression were very similar between Pten; p53 cKO and
triple cKO tumors; however, there were no amplifications of
Met or Egfr in triple cKO tumors, where G1 cell cycle checkpoint
control was compromised by Rb1 deletion. This implies that the
initiating mutations may strongly influence the selective advan-
tage of hyperactivation of specific RTKs. The more uniform
involvement of Pdgfra indicates that it may play a unique role
relative to other RTKs. Further investigation is needed to delin-
eate the mechanisms driving different selective pressures for
RTK amplifications in Pten; p53 cKO and triple cKO tumors.
Figure 7. Genome-Wide CNAs in Murine HGAs
Heat map of genomic CN imbalances showing segmented log2 ratio from aCGH data to identify CN gains (red) and losses (blue) in 50 Pten; p53 cKO (white bar)
and 21 triple cKO (black bar) tumors. Amplifications and gains of genes encoding the RTKs Met (green bars), Egfr (orange bars), and Pdgfr-a (violet bars) are
shown. Tumors with amplifications of the cell cycle-related genes shown in Table S2 are also indicated (brown bars). Chr numbers are indicated on the right,
and frequent losses of Chr12 and Chr14 are boxed. Color scale with corresponding log2 ratio value is to the right. See also Figure S6.
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cKO tumors, showing a selective pressure for activation of PI3K
signaling regardless of whether tumors were initiated by a muta-
tion in this pathway.
Dysregulation of RB signaling leading to G1/S progression
appears to be a critical event in gliomagenesis. This pathway
was also targeted by somatic amplifications, with Pten; p53
cKO tumors showing amplification of Rb regulators as well as
other cell cycle genes and triple cKO tumors showing amplifica-
tion of pathway components downstream of Rb (Table S2).
Again, we noted alterations in multiple pathway members in
the same tumor, suggesting that pathway mutations cooperate
to provide a greater selective advantage.
Relevance of the Mouse HGA Models to Human Disease
The murine HGAs reported here are relevant to human disease,
reflecting a spectrum of tumor histology and molecular features.
In addition to focal amplifications and deletions of known glioma
genes, large-scale chromosomal losses in regions syntenic to
those lost in humanHGAwere detected. Gene expression signa-
tures from gliomas arising in Pten; p53 or triple cKOmice fell into
three subgroups showing significant similarity to the three
expression subclasses of human high-grade glioma associated
with tumor prognosis (Phillips et al., 2006). Importantly, tumor
subgroups did not correlate with initiating mutations or tumor
histology (Figure 8A). In humans the Mesenchymal subgroup is
associated with the worse prognosis (Phillips et al., 2006). Unex-
pectedly, 78% (seven of nine) of the mouse tumors with greatest
similarity to the Mesenchymal subgroup arose as exophytic
tumors from the ventral base of the brain or the pons (Figure 8).
Conversely, 78% (seven of nine) of tumors from this location hada Mesenchymal gene signature compared to 7% (two of 29) of
HGAs in all other locations of the central nervous system (p =
0.00009), suggesting that the microenvironment or specific cells
targeted in this region of brain contributed to tumor phenotype.
Taken together, the somatically acquired genomic imbalances
and the gene expression signatures of HGAs in Pten; p53 cKO
and triple cKO mice indicate that similar selective pressures
drive gliomagenesis and generate similar tumors in humans
and these mouse models, suggesting that they should be valu-
able for preclinical testing.
EXPERIMENTAL PROCEDURES
Mice
Mice were maintained on a predominantly FVB/NJ background with contribu-
tions from 129/SV and C57Bl6. The GFAP-CreERTMA (FVB/NJ background)
and floxed Pten (backcrossed six generations to FVB/NJ) mouse lines have
been previously described (Chow et al., 2008; Suzuki et al., 2001) and were
crossed to generate GFAP-CreER; PtenloxP/loxP mice. Controls were
PtenloxP/loxP mice injected with tamoxifen, orCreER; PtenloxP/loxP mice injected
with vehicle. Floxed Tp53 and Rb1 mice were obtained from the Mouse
Models of Human Cancer Consortium repository (Jonkers et al., 2001; Marino
et al., 2000). All combinations of compound floxed mice were generated by
crossing GFAP-CreER; PtenloxP/loxP with Tp53; Rb1 double-floxed mice.
Tamoxifen (Sigma-Aldrich, St. Louis. MO, USA) was dissolved in corn oil
(Sigma-Aldrich) at a concentration of 20 mg/ml at 37C, filter sterilized, and
stored for up to 7 days at 4C in the dark. A 27G needle tuberculin syringe (Bec-
tonDickinson, Franklin Lakes, NJ, USA) was used for intraperitoneal injections.
Tamoxifen (9mg/40 g body weight) was administered daily for 3 days after P28
(range P25–P49). There was no significant difference associated with the age
of induction in the time from tamoxifen administration to tumor onset, or in the
histology of the resulting tumors. Procedures for all mouse experiments were
reviewed and approved by the Animal Care and Use Committee at St. Jude
Children’s Research Hospital, and are in compliance with national andCancer Cell 19, 305–316, March 15, 2011 ª2011 Elsevier Inc. 313
Figure 8. Gene Expression Signatures of Mouse HGAs Are Similar to Human Gene Expression Subgroups
(A) Gene expression profiles generated from Pten; p53 cKO (Model: white bars) and triple cKO (Model: black bars) HGAs were analyzed by unsupervised
hierarchical clustering using the top 1000 probe sets showing the greatest differential expression levels as selected by median absolute deviation scores. Three
primary clusters were identified, HC1–HC3, and the dendrogram is shown on top. The heat map shows the most upregulated probe sets for each cluster derived
using linear models algorithm. The primary histological features (Histology) are glioblastoma (yellow bars), HGA with myxoid degeneration (light-blue bars),
anaplastic astrocytoma (purple bars), anaplastic oligoastrocytoma (dark-green bar), and one tumor (gray bar), which was not determined. Tumors with RTK
and cell cycle-related gene mutations are indicated as in Figure 6. Tumors located at the base of the brain are marked with arrowheads. Color scale with
corresponding Z-score values is to the right.
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NIH guidelines.
Mouse Tissue Collection
Mice were perfused with 13 phosphate-buffered saline (PBS) to exsanguinate
tissues. Following dissection, half the brain containing a portion of the tumor, if
evident, was fixed by immersion in 4% paraformaldehyde (PFA) in 13 PBS at
4C overnight. If no tumor could be visually identified, the brain was divided
sagittally, and both halves were fixed in this manner. The tissue was pro-
cessed, embedded in paraffin, and 5 mm sections were cut. If the presence
of a tumor was evident, several slides spanning the tumor were stained with
H&E; if a tumor was not grossly apparent, every fifth slide was stained
spanning the entire brain. All slides were examined by L.M.L.C., and sections
containing tumor or other anomalies were viewed by S.J.B. and assigned diag-
noses by D.W.E., a clinical neuropathologist. The second half of the tumor-
containing brains was further dissected to separate tumor tissue from normal
cortex. Several tubes of each if possible were immediately flash frozen on dry
ice pellets for subsequent nucleic acid and/or protein preparations.
Mouse Tumor Analyses
Tumor diagnoses were assigned by D.W.E., a neuropathologist. Microarray
analyses were performed using Roswell Park Cancer Institute (RPCI) 6.5K
mouse BAC array, and Agilent mouse 244K Oligo array for array CGH, and
Affymetrix Mouse Genome 430 2.0 chip for expression profiles.
Human Tumor Samples
Snap-frozen surgical samples of grade II exophytic brain stem gliomas or
autopsy samples of normal brain stem were obtained from the St. Jude tumor
bank. Histopathology was reviewed by D.W.E. These samples were collected
and experiments performed with the informed consent of patients and/or their
legal guardians under the approval of the St. Jude Children’s Research
Hospital Institutional Review Board.
Statistical Analysis
For categorical statistical analysis, we used two-sided Fisher’s exact test.
ACCESSION NUMBERS
Array data is deposited in Gene Expression Omnibus (GEO) under accession
number GSE22927.
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